PET imaging with 89Zr: From radiochemistry to the clinic
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
The advent of antibody-based cancer therapeutics has led to the concomitant rise in the development of companion diagnostics for these therapies, particularly nuclear imaging agents. A number of radioisotopes have been employed for antibody-based PET and SPECT imaging, notably 64Cu, 124I, 111In, and 99mTc; in recent years, however, the field has increasingly focused on 89Zr, a radiometal with near ideal physical and chemical properties for immunoPET imaging. In the review at hand, we seek to provide a comprehensive portrait of the current state of 89Zr radiochemical and imaging research, including work into the production and purification of the isotope, the synthesis of new chelators, the development of new bioconjugation strategies, the creation of novel 89Zr-based agents for preclinical imaging studies, and the translation of 89Zr-labeled radiopharmaceuticals to the clinic. Particular attention will also be dedicated to emerging trends in the field, 89Zr-based imaging applications using vectors other than antibodies, the comparative advantages and limitations of 89Zr-based imaging compared to that with other isotopes, and areas that would benefit from more extensive investigation. At bottom, it is hoped that this review will provide both the experienced investigator and new scientist with a full and critical overview of this exciting and fast-developing field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shannon, R. D. (1976) · Acta Crystallographica Section A · doi:10.1107/s0567739476001551 · Cited by 66,145
Critical Stability Constants: First Supplement
Martell, A. E., & Smith, R. M. (1982) · Springer eBooks · doi:10.1007/978-1-4615-6761-5 · Cited by 6,008
Smith, R. M., & Martell, A. E. (1975) · Springer eBooks · doi:10.1007/978-1-4613-4452-0 · Cited by 2,264
Arming antibodies: prospects and challenges for immunoconjugates
Wu, A. M., & Senter, P. D. (2005) · Nature Biotechnology · doi:10.1038/nbt1141 · Cited by 1,052
Wadas, T. J., Wong, E. H., Weisman, G. R., & Anderson, C. J. (2010) · Chemical Reviews · doi:10.1021/cr900325h · Cited by 924
Dijkers, E. C., Oude Munnink, T. H., Kosterink, J. G., Brouwers, A. H., Jager, P. L., de Jong, J. R., van Dongen, G. A., Schröder, C. P., Lub-de Hooge, M. N., & de Vries, E. G. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.12 · Cited by 805
A Family of Zirconium Complexes Having Two Phenoxy−Imine Chelate Ligands for Olefin Polymerization
Matsui, S., Mitani, M., Saito, J., Tohi, Y., Makio, H., Matsukawa, N., Takagi, Y., Tsuru, K., Nitabaru, M., Nakano, T., et al. (2001) · Journal of the American Chemical Society · doi:10.1021/ja0032780 · Cited by 479
89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo
Holland, J. P., Divilov, V., Bander, N. H., Smith-Jones, P. M., Larson, S. M., & Lewis, J. S. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.076174 · Cited by 418
Self-citationStandardized methods for the production of high specific-activity zirconium-89
Holland, J. P., Sheh, Y., & Lewis, J. S. (2009) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2009.05.007 · Cited by 408
Self-citationDevelopment and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging
Dijkers, E. C. F., Kosterink, J. G. W., Rademaker, A. P., Perk, L. R., van Dongen, G. A. M. S., Bart, J., de Jong, J. R., de Vries, E. G. E., & Lub-de Hooge, M. N. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.060392 · Cited by 334
Cited by
Matching chelators to radiometals for radiopharmaceuticals
Price, E. W., & Orvig, C. (2014) · Chem. Soc. Rev. · doi:10.1039/c3cs60304k · Cited by 1,018
Tumour targeting with radiometals for diagnosis and therapy
Ramogida, C. F., & Orvig, C. (2013) · Chemical Communications · doi:10.1039/c3cc41554f · Cited by 255
Molecular imaging of the tumor microenvironment
Zhou, Z., & Lu, Z.-R. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.07.012 · Cited by 253
Engineered antibodies for molecular imaging of cancer
Wu, A. M. (2014) · Methods · doi:10.1016/j.ymeth.2013.09.015 · Cited by 166
Zeglis, B. M., Davis, C. B., Aggeler, R., Kang, H. C., Chen, A., Agnew, B. J., & Lewis, J. S. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400122c · Cited by 160
Self-citationPhenomic studies on diseases: potential and challenges
Ying, W. (2023) · Phenomics · doi:10.1007/s43657-022-00089-4 · Cited by 96
“The hybrid imaging equipment can achieve the distinct technical merits of both imaging techniques: it can obtain patients' medical images in both microscopic and macroscopic scale in the same platform, which can indicate the pathological state of patients in molecular, structural and functional aspects (Tian et al. 20…”
Influential
Metadata
- Authors
- Deri, M. A., Zeglis, B. M., Francesconi, L. C., & Lewis, J. S.
- Venue
- Nuclear Medicine and Biology
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 40
- Issue
- 1
- Pages
- 3-14
- ISSN
- 0969-8051 (ISSN-L)
- OpenAlex
- W2017307891
- Cited by
- 423
- References
- 50
- FWCI
- 14.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.